Search

Displaying results 1921 - 1930 of 10000 in total
  1. Drug

    ZYC300

    go.drugbank.com/drugs/DB04986
    Investigational

    ZYC300 is a plasmid DNA of CYP1B1 encapsulated in biodegradable poly-DL-lactide-coglycolide microparticles. … It is designed as a vaccine, intended to increase immune system sensitivity to CYP1B1, an enzyme highly prevalent in tumor cells.

  2. Drug

    Butamben

    go.drugbank.com/drugs/DB11148
    ApprovedWithdrawn

    Butamben is a local anesthetic in the form of n-butyl-p-aminobenzoate. … [A27147] Its structure corresponds to the standard molecule of a hydrophilic and hydrophobic domain separated by an intermediate ester found in most of the local anesthetics.

    Mixtures: One Touch Advanced Topical Anesthetic Gel Cool Mint
  3. Drug

    VidPrevtyn Beta

    go.drugbank.com/drugs/DB16427
    Approved

    [L49691] It comprises a recombinant SARS-CoV-2 spike protein (B.1.351 strain) - produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from … [A245829,L49696] In October 2022, VidPrevtyn Beta was approved in the European Union for use as a booster dose in patients who have previously received a COVID-19 vaccine.[L49691]

  4. Drug

    Kojic acid

    go.drugbank.com/drugs/DB01759
    Approved

    Mixtures: Eye GelCategories: Compounds used in a research, industrial, or household setting
  5. Drug

    Anvatabart opadotin

    go.drugbank.com/drugs/DB18290
    Investigational

    Synonyms: Immunoglobulin G1 [121-(4-acetylphenylalanine),de-450-lysine], anti-(human epidermal growth factor receptor HER2) (human-Mus musculus monoclonal Amab788 γ1-chain), disulfide with human-Mus musculus monoclonal
  6. Drug

    Phenazopyridine

    go.drugbank.com/drugs/DB01438
    ApprovedInvestigational

    In the USA, this drug was previously marked by Roche but has been discontinued by the FDA.[L7832] It is still used in various parts of the world. … Ingestion of phenazopyridine is found to change the appearance of the urine by imparting an orange or red color, as it is considered an azo dye.[L7829]

    Mixtures: All-In-One UTI Emergency Kit, All-In-One UTI Emergency Kit
  7. Drug

    Moxidectin

    go.drugbank.com/drugs/DB11431
    ApprovedInvestigationalVet approved

    It was first used in cattle followed by an approved use in general animals. It is a semi-synthetic methoxine derivative of nemadectin which is a 16-member pentacyclic lactone of the milbemycin class. … [A33385] Moxidectin was developed by Medicines Development for Global Health and FDA approved in June 13, 2018.[L2970]

    Mixtures: Advocate Spot-on Solution for Small Dogs, Advocate Spot-on Solution for Large DogsCategories: Compounds used in a research, industrial, or household setting
  8. Drug

    Pertuzumab

    go.drugbank.com/drugs/DB06366
    ApprovedInvestigational

    Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). … It was first approved by the FDA in 2012 for use with [docetaxel] and another HER2-targeted monoclonal antibody, [trastuzumab], in the treatment of metastatic HER2-positive breast cancer.

  9. Drug

    Freneslerbart

    go.drugbank.com/drugs/DB19080
    Investigational

    Freneslerbart is under investigation in clinical trial NCT04981717 (A Study to Examine the Efficacy and Safety of Anti-fel D 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic

    Synonyms: Anti-cat allergen fel d 1 monoclonal anitbody regn-1908, Immunoglobulin G4 [227-proline], anti-(Felis catus allergen Fel d1) (human monoclonal REGN1908 γ4-chain), disulfide with human monoclonal REGN1908 κ-chain, dimer
  10. Drug

    Brexucabtagene autoleucel

    go.drugbank.com/drugs/DB15699
    ApprovedInvestigational

    These therapies differ in manufacturing methodology, viral vector, chimeric antigen choice, and the internal co-stimulatory domains of the chimeric antigen. … A216163, L15148] However, the preparation of brexucabtagene autoleucel, previously referred to as KTE-X19, uses a method of T cell enrichment that decreases the prevalence of CD19-expressing tumour cells in